Sapiens Reports First Quarter 2023 Financial Results

Avi Shekhtman

May 3, 2023

 May 3, 2023Sapiens International Corporation, (NASDAQ and TASE: SPNS), a leading global provider of software solutions for the insurance industry, today announced its financial results for the first quarter ended March 31, 2023.

Summary Results for First Quarter 2023 (USD in millions, except per share data)

  GAAP   Non-GAAP  
  Q1 2023 Q1 2022 % Change Q1 2023 Q1 2022 % Change
Revenue $124.7 $117.7  6.0% $124.8 $117.7  6.0%
Gross Profit $53.0 $49.4  7.3% $56.4 $52.9  6.5%
Gross Margin 42.5%  42.0%  50 bps 45.2%  45.0%  20 bps
Operating Income $18.9 $16.5  14.2% $22.5 $20.8  8.4%
Operating Margin 15.1%  14.1%  100 bps 18.0%  17.6%  40 bps
Net Income (*) $14.2 $13.9  1.9% $17.3 $17.3  -0.3%
Diluted EPS $0.26 $0.25  4.0% $0.31 $0.31  0.0%

 (*) Attributable to Sapiens’ shareholders

“Sapiens delivered a strong first quarter, with operating profit increasing year-over-year by 8.4% on revenue growth of 6%, which resulted in an operating margin of 18.0%,” stated Roni Al-Dor, President and CEO of Sapiens. “Our diligence and extensive groundwork in North America are now paying off as the region returns to growth. In the first quarter revenue in North America increased by 2.8% compared to last year.  We ended 2022 with significant enhancements in our products, delivery, and talent that helped us build a momentum that has carried over into 2023.  We have already signed new deals for P&C, Life, and Reinsurance since the beginning of the year and are optimistic by the quality of our new business pipeline.

Mr. Al-Dor continued, “Revenue growth in the first quarter was driven by a year-over-year increase of 9.0% in Europe. Our customer-centric model, implemented globally, has consistently driven growth and profitability while generating cash flow.”

We are well-positioned to continue our positive momentum from the first quarter throughout the remainder of the year. We are increasing our full-year 2023 non-GAAP revenues to $507 million to $512 million compared to our previous guidance of $502 million to $507 million. We are also increasing the guidance for the full year 2023 non-GAAP operating margin to 17.8%-18.2%, compared to our previous guidance of 17.6% to 18.0%. These revised targets demonstrate our commitment to delivering outstanding results and driving sustained growth,” concluded Mr. Al-Dor.

Quarterly Results Conference Call

Management will host a conference call and webcast on May 3, 2023, at 9:30 a.m. Eastern Time (4:30 p.m. in Israel) to review and discuss Sapiens’ results. Please call the following numbers (at least 10 minutes before the scheduled time) to participate:

  • North America (toll-free): 1-888-642-5032
  • International: 972-3-918-0609
  • UK: 0-800-917-5108

The live webcast of the call can be viewed on Sapiens’ website at: https://www.sapiens.com/investor-relations/ir-events-presentations. A replay of the call will be available one business day following the completion of the event, at the same link for 90 days.

Non-GAAP Financial Measures

This press release contains the following non-GAAP financial measures: non-GAAP revenue, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income attributed to Sapiens shareholders, non-GAAP basic and diluted earnings per share, Adjusted EBITDA and Adjusted Free Cash-Flow.

Sapiens believes that these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to Sapiens’ financial condition and results of operations. The Company’s management uses these non-GAAP measures to compare the Company’s performance to that of prior periods for trend analyses, for purposes of determining executive and senior management incentive compensation and for budgeting and planning purposes. These measures are used in financial reports prepared for management and in quarterly financial reports presented to the Company’s board of directors. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends, and in comparing the Company’s financial measures with other software companies, many of which present similar non-GAAP financial measures to investors.

Non-GAAP financial measures consist of GAAP financial measures adjusted to exclude: Valuation adjustment on acquired deferred revenue, amortization of capitalized software development and other intangible assets, capitalization of software development, stock-based compensation, compensation related to acquisition and acquisition-related costs, restructuring and cost reduction costs, and tax adjustments related to non-GAAP adjustments.

Management of the Company does not consider these non-GAAP measures in isolation, or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements. In addition, they are subject to inherent limitations, as they reflect the exercise of judgment by management about which expenses and income are excluded or included in determining these non-GAAP financial measures.

To compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. Sapiens urges investors to review the reconciliation of its non-GAAP financial measures to the comparable GAAP financial measures, which it includes in press releases announcing quarterly financial results, including this press release, and not to rely on any single financial measure to evaluate the Company’s business.

Reconciliation tables of the most comparable GAAP financial measures to the non-GAAP financial measures used in this press release are included with the financial tables of this release.

The Company defines Adjusted EBITDA as net profit, adjusted to eliminate valuation adjustment on acquired deferred revenue, stock-based compensation expense, depreciation and amortization, capitalization of software development costs, compensation expenses related to acquisition and acquisition-related costs, restructuring and cost reduction costs, financial expense (income), provision for income taxes and other income (expenses). These amounts are often excluded by other companies as well, in order to help investors understand the operational performance of their business.

The Company uses Adjusted EBITDA as a measurement of its operating performance, because it assists in comparing the operating performance on a consistent basis by removing the impact of certain non-cash and non-operating items. Adjusted EBITDA reflects an additional way of viewing aspects of the operations that the Company believes, when viewed with the GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provide a more complete understanding of factors and trends affecting its business. The Company uses Adjusted Free Cash-Flow as a measurement of its operating performance, and reconciles cash-flow from operating activities to Adjusted Free Cash-Flow, while reducing the amounts for capitalization of software development costs and capital expenditures. The Company adds back cash payments made for former acquisitions in respect of future performance targets and retention criteria as determined upon acquisition date of the respective acquired company, which were included in the cash-flow from operating activities. We believe that Adjusted Free Cash-Flow is useful in evaluating our business, because Adjusted Free Cash-Flow reflects the cash surplus available to fund the expansion of our business.

About Sapiens

Sapiens International Corporation (NASDAQ and TASE: SPNS) empowers the financial sector, with a focus on insurance, to transform and become digital, innovative, and agile. With more than 40 years of industry expertise, Sapiens’ cloud-based SaaS insurance platform offers pre-integrated, low-code capabilities across core, data and digital domains to accelerate our customers’ digital transformation. Serving over 600 customers in 30 countries, Sapiens offers insurers across property and casualty, workers’ compensation, and life insurance markets the most comprehensive set of solutions, from core to complementary, including Reinsurance, Financial & Compliance, Data & Analytics, Digital, and Decision Management.  For more information visit www.sapiens.com or follow us on LinkedIn.

 

Investor and Media Contact

Yaffa Cohen-Ifrah
Chief Marketing Officer and Head of Investor Relations, Sapiens
Yaffa.cohen-ifrah@sapiens.com
+1 917-533-4782

 

Investors Contact

Brett Maas
Managing Partner, Hayden IR
+1 646-536-7331
Brett.Maas@HaydenIR.com

Kimberly Rogers
Managing Director, Hayden IR
+1 541-904-5075
kim@HaydenIR.com

 

 

Forward Looking Statements

Certain matters discussed in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, and are based on our beliefs, assumptions and expectations, as well as information currently available to us. Such forward-looking statements may be identified by the use of the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “will,” “plan” and similar expressions. Such statements reflect our current views with respect to future events and are subject to certain risks and uncertainties. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: the degree of our success in our plans to leverage our global footprint to grow our sales; the degree of our success in integrating the companies that we have acquired through the implementation of our M&A growth strategy; the lengthy development cycles for our solutions, which may frustrate our ability to realize revenues and/or profits from our potential new solutions; our lengthy and complex sales cycles, which do not always result in the realization of revenues; the degree of our success in retaining our existing customers or competing effectively for greater market share; difficulties in successfully planning and managing changes in the size of our operations; the frequency of the long-term, large, complex projects that we perform that involve complex estimates of project costs and profit margins, which sometimes change mid-stream; the challenges and potential liability that heightened privacy laws and regulations pose to our business; occasional disputes with clients, which may adversely impact our results of operations and our reputation; various intellectual property issues related to our business; potential unanticipated product vulnerabilities or cybersecurity breaches of our or our customers’ systems; risks related to the insurance industry in which our clients operate; risks associated with our global sales and operations, such as changes in regulatory requirements, wide-spread viruses and epidemics like the recent novel coronavirus pandemic, which adversely affected our results of operations, or fluctuations in currency exchange rates; and risks related to our principal location in Israel and our status as a Cayman Islands company. While we believe such forward-looking statements are based on reasonable assumptions, should one or more of the underlying assumptions prove incorrect, or these risks or uncertainties materialize, our actual results may differ materially from those expressed or implied by the forward-looking statements. Please read the risks discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F, which we filled with the SEC on March 31, 2022, in order to review conditions that we believe could cause actual results to differ materially from those contemplated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES                

CONDENSED CONSOLIDATED STATEMENT OF INCOME

U.S. dollars in thousands (except per share amounts)

  Three months ended
 March 31,
2023 2022
 (unaudited)  (unaudited)
 Revenue 124,721   117,695  
 Cost of revenue 71,692   68,278  
       
 Gross profit 53,029   49,417  
       
 Operating expenses:        
 Research and development, net 15,617   14,150  
 Selling, marketing, general and administrative 18,519   18,719  
 Total operating expenses 34,136   32,869  
       
 Operating income 18,893   16,548  
       
 Financial and other expenses (income), net 1,197   (348)  
 Taxes on income 3,330   2,938  
       
       
 Net income 14,366   13,958  
       
 Attributable to non-controlling interest 170   32  
       
 Net income attributable to Sapiens’ shareholders 14,196   13,926  
       
       
 Basic earnings per share 0.26   0.25  
       
 Diluted earnings per share 0.26   0.25  
       
         
Weighted average number of shares outstanding used to compute basic earnings per share (in thousands) 55,156   55,093  
           
Weighted average number of shares outstanding used to compute diluted earnings per share (in thousands) 55,570   55,630  

SAPIENS INTERNATIONAL CORPORATION N.V. AND SUBSIDIARIES           

RECONCILIATION OF GAAP TO NON-GAAP RESULTS

U.S. dollars in thousands (except per share amounts)

    Three months ended  
    March 31,  
    2023   2022  
    (unaudited)   (unaudited)  
           
GAAP revenue   124,721   117,695  
Valuation adjustment on acquired deferred revenue   55   23  
Non-GAAP revenue   124,776   117,718  
           
GAAP gross profit   53,029   49,417  
Revenue adjustment    55   23  
Amortization of capitalized software    1,431   1,471  
Amortization of other intangible assets    1,848   2,032  
Non-GAAP gross profit   56,363   52,943  
           
GAAP operating income   18,893   16,548  
Gross profit adjustments   3,334   3,526  
Capitalization of software development   (1,658)   (1,746)  
Amortization of other intangible assets   1,076   1,244  
Stock-based compensation   863   931  
Acquisition-related costs (*)   6   267  
Non-GAAP operating income   22,514   20,770  
           
  GAAP net income attributable to Sapiens’ shareholders   14,196   13,926  
  Operating income adjustments   3,621   4,222  
  Taxes on income   (564)   (850)  
  Non-GAAP net income attributable to Sapiens’ shareholders   17,253   17,298  
           

(*) Acquisition-related costs pertain to charges on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as tax, accounting and legal rendered until the acquisition date.

Adjusted EBITDA Calculation
U.S. dollars in thousands

    Three months ended  
 March 31,
2023 2022
GAAP operating profit   18,893   16,548  
           
Non-GAAP adjustments:          
Valuation adjustment on acquired deferred revenue   55   23  
Amortization of capitalized software   1,431   1,471  
Amortization of other intangible assets   2,924   3,276  
Capitalization of software development   (1,658)   (1,746)  
Stock-based compensation   863   931  
Compensation related to acquisition and acquisition-related costs   6   267  
           
Non-GAAP operating profit   22,514   20,770  
           
Depreciation   1,055   1,140  
           
Adjusted EBITDA   23,569   21,910  
           
           

Summary of NON-GAAP Financial Information
U.S. dollars in thousands (except per share amounts)

Q1 2023   Q4 2022   Q3 2022   Q2 2022   Q1 2022
                   
Revenues 124,776   119,486   119,019   118,605   117,718
Gross profit 56,363   53,774   53,546   53,207   52,943
Operating income 22,514   21,058   20,902   20,747   20,770
Adjusted EBITDA 23,569   22,092   22,036   21,681   21,910
Net income to Sapiens’ shareholders 17,253   18,022   16,871   14,979   17,298
                   
Diluted earnings per share 0.31   0.32   0.30   0.27   0.31

Non-GAAP Revenues by Geographic Breakdown
U.S. dollars in thousands

Q1 2023   Q4 2022   Q3 2022   Q2 2022   Q1 2022
                   
North America 50,371   50,801   49,555   48,154   49,009
Europe 64,572   56,910   56,887   59,868   59,267
Rest of the World 9,833   11,775   12,577   10,583   9,442
                   
Total 124,776   119,486   119,019   118,605   117,718

 Non-GAAP Revenue breakdown

U.S. dollars in thousands

Q1 2023   %   Q1 2022   %
               
Software products and re-occurring post-production services (*) 81,842   65.6%   75,625   64.2%
Pre-production implementation services (**) 42,934   34.4%   42,093   35.8%
               
Total Revenues 124,776   100%   117,718   100%
               

 

Q1 2023   Q1 2022
       
Software products and re-occurring post-production services (*) 44,849   40,446
Pre-production implementation services (**) 11,514   12,497
       
Total Gross profit 56,363   52,943
       

 

Q1 2023   Q1 2022
       
Software products and re-occurring post-production services (*) 54.8%   53.5%
Pre-production implementation services (**) 26.8%   29.7%
       
Gross margin 45.2%   45.0%

 (*) Software products and re-occurring post-production services include mainly term license, maintenance, cloud solutions, subscription, and post-production services. This revenue stream is a mix of recurring and re-occurring in nature.

(**) Pre-production implementation services include mainly implementation services before go-live, which are one-time in nature.

Adjusted Free Cash-Flow
U.S. dollars in thousands

Q1 2023   Q4 2022   Q3 2022   Q2 2022   Q1 2022
                   
Cash-flow from operating activities 22,188   14,430   4,405   6,615   18,330
Increase in capitalized software development costs (1,658)   (1,238)   (1,492)   (1,621)   (1,746)
Capital expenditures (634)   (400)   (1,047)   (803)   (453)
Free cash-flow 19,896   12,792   1,866   4,191   16,131
                   
Cash payments attributed to acquisition-related costs(*) (**) 30   1,100      
                   
Adjusted free cash-flow 19,926   13,892   1,866   4,191   16,131

(*) Included in cash-flow from operating activities

(**) Acquisition-related payments pertain to payments on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as, tax, accounting and legal rendered until the acquisition date.

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEET

U.S. dollars in thousands

March 31, December 31,
2023 2022
 (unaudited)  (unaudited)
 
 ASSETS  
 
 CURRENT ASSETS  
Cash and cash equivalents  116,654    160,285
  Short-term bank deposit    65,000    20,000
Trade receivables, net and unbilled receivables  94,833    93,382
Other receivables and prepaid expenses 11,624   11,640
Total current assets 288,111   285,307
     
 LONG-TERM ASSETS    
Property and equipment, net 11,612   12,021
Severance pay fund 3,672   3,996
Goodwill and intangible assets, net 316,865   319,661
  Operating lease right-of-use assets   27,439   33,688
Other long-term assets 15,619   13,671
Total long-term assets 375,207   383,037
     
 TOTAL ASSETS 663,318   668,344
     
LIABILITIES AND EQUITY    
     
 CURRENT LIABILITIES    
Trade payables 2,467    9,415
  Current maturities of Series B Debentures    19,796    19,796
Accrued expenses and other liabilities  80,911    76,962
  Current maturities of operating lease liabilities    6,883    9,063
Deferred revenue  38,920    30,720
  Total current liabilities   148,977   145,956
     
 LONG-TERM LIABILITIES    
Series B Debentures, net of current maturities   39,493    59,275
  Deferred tax liabilities    12,193    11,363
  Other long-term liabilities    13,097   13,312
  Long-term operating lease liabilities    24,686    28,432
  Redeemable non-controlling interest    87    89
Accrued severance pay  6,903    7,063
Total long-term liabilities 96,459   119,534
     
EQUITY 417,882   402,854
     
TOTAL LIABILITIES AND EQUITY 663,318   668,344
         

 SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENT OF CASH FLOW
U.S. dollars in thousands

For the three months ended March 31,
  2023   2022
  (unaudited)   (unaudited)
Cash flows from operating activities:      
Net income 14,366   13,958
Reconciliation of net income to net cash provided by operating activities:      
Depreciation and amortization 5,410   5,887
Accretion of discount on series B debentures 14   18
Capital (gain) loss from sale of property and equipment (10)   7
Stock-based compensation related to options issued to employees 863   931
       
Net changes in operating assets and liabilities, net of amount acquired:      
Increase in trade receivables, net and unbilled receivables (2,039)   (7,357)
Increase (decrease) in deferred tax liabilities, net 25   (471)
Decrease in other operating assets 1,257   959
Decrease in trade payables (7,014)   (34)
Increase (decrease) in other operating liabilities 1,197   (1,136)
Increase in deferred revenues 7,936   5,526
Increase in accrued severance pay, net 183   42
Net cash provided by operating activities 22,188   18,330
       
Cash flows from investing activities:      
       
Purchase of property and equipment (653)   (453)
Investment in deposits (45,004)   (15,033)
Proceeds from sale of property and equipment 19  
Capitalized software development costs (1,658)   (1,746)
Acquisition of intellectual property (177)  
Net cash used in investing activities (47,473)   (17,232)
       
Cash flows from financing activities:      
       
Repayment of series B debenture (19,796)   (19,796)
Dividend to non-controlling interest (47)  
Net cash used in financing activities (19,843)   (19,796)
       
Effect of exchange rate changes on cash and cash equivalents 1,497   (236)
       
Increase (Decrease) in cash and cash equivalents (43,631)   (18,934)
Cash and cash equivalents at the beginning of period  160,285   190,243
     
Cash and cash equivalents at the end of period 116,654   171,309

Debentures Covenants

As of March 31, 2023, Sapiens was in compliance with all of its financial covenants under the indenture for the Series B Debentures, based on having achieved the following in its consolidated financial results:

Covenant 1

  • Target shareholders’ equity (excluding non-controlling interest): above $120 million.
  • Actual shareholders’ equity (excluding non-controlling interest) equal to $415.4

Covenant 2

  • Target ratio of net financial indebtedness to net capitalization (in each case, as defined under the indenture for the Company’s Series B Debentures) below 65%.
  • Actual ratio of net financial indebtedness to net capitalization equal to (41.17)%.

Covenant 3

  • Target ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is below 5.5.
  • Actual ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is equal to (1.36).
  • General Press Releases
  • Investors Press Releases